CoChat
Sign Up
Cited by 140Treatment of Major DepressionAttention Deficit Hyperactivity DisorderElectroconvulsive Therapy Studies

The DOI matches its Crossref record; 10 of the 11 references it cites were found in a registry or an index.

A Randomized, Double-blind, Placebo-controlled Trial of Augmentation With an Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression

Patkar, Ashwin A., Masand, Prakash S., Pae, Chi-Un, Peindl, Kathleen, Hooper-Wood, Christa, Mannelli, Paolo, Ciccone, Patrick·2006·Journal of Clinical Psychopharmacology
DOI 10.1097/01.jcp.0000246212.03530.fd
Open this paper in CoChat — free account

Abstract

We examined the efficacy and tolerability of augmentation with an extended release formulation of methylphenidate (OROS MPH, Concerta) in patients with major depression who were nonresponders or partial responders to antidepressants. Sixty subjects with treatment-resistant depression (TRD) participated in a 4-week, randomized, double-blind, placebo-controlled study of augmentation with methylphenidate (18-54 mg/d). The preexisting antidepressant dose was unchanged. The primary efficacy measure was change in the 21-item Hamilton Depression Rating Scale from randomization to end of treatment. Data were analyzed with intent-to-treat with last observation carried forward approach. There were no statistically significant differences between the methylphenidate (n = 30) and placebo (n = 30) groups in reduction in 21-item Hamilton Depression Rating Scale scores (drug, -6.9; placebo, -4.7) from baseline to end of treatment (F1,47 = 1.24, P = 0.22), although responders were numerically higher in the extended-release methylphenidate group (40.0%) than in the placebo group (23.3%). On the secondary efficacy measures of changes in Clinical Global Impression-Improvement and Severity scores and Beck Depression Inventory-Second Edition, the drug failed to separate from placebo, although the proportion of responders in the drug group were numerically higher than placebo. There were no significant differences in weight, heart rate, and blood pressure changes between the 2 groups. The common adverse events were loss of appetite, nausea, headache, and anxiety. The mean dose of drug was 34.2 mg/d. The study did not demonstrate a statistically significant benefit for augmentation with methylphenidate in TRD. Combination of methylphenidate with antidepressants was well tolerated. Adequately powered, randomized, controlled trials are necessary to fully evaluate the efficacy of extended-release methylphenidate in TRD.

Overview

Integrity signals

Registry

Crossref · 10.1097/01.jcp.0000246212.03530.fd

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 11 references

Research works printed but not linked: 1

  1. Masand, 1997, Psychostimulant augmentation of second generation antidepressants., Depress Anxiety, 6, 42

Cited by

Sorted by citations

Items 101–140 of 140

Related

See all

Metadata

Authors
Patkar, A. A., Masand, P. S., Pae, C.-U., Peindl, K., Hooper-Wood, C., Mannelli, P., & Ciccone, P.
Affiliations
  • Duke University (US)
  • Duke Medical Center (US)
Corresponding author
  • Patkar, Ashwin A.
  • Masand, Prakash S.
  • Pae, Chi-Un
  • Peindl, Kathleen
  • Mannelli, Paolo
ORCID
Venue
Journal of Clinical Psychopharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2006-12
Volume
26
Issue
6
Pages
653-656
ISSN
0271-0749 (ISSN-L)
DOI
10.1097/01.jcp.0000246212.03530.fd
OpenAlex
W2051933342
Cited by
140
References
11
Citations by year
2026: 2 · 2025: 6 · 2024: 3 · 2023: 4 · 2022: 9 · 2021: 5 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 7 · 2016: 7 · 2015: 14 · 2014: 7 · 2013: 11 · 2012: 6
FWCI
8.15
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
treatment-resistant depression, methylphenidate, sustained-release formulation, antidepressant augmentation, major depressive disorder, drug efficacy, tolerability, adverse events
MeSH terms
Adolescent, Adult, Aged, Central Nervous System Stimulants, Antidepressive Agents, Delayed-Action Preparations, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Methylphenidate, Middle Aged, Psychiatric Status Rating Scales, Time Factors, Treatment Outcome, Treatment Failure, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review